Issue 36

PSYCH Investor Summit: Research & Development – HAPPENING LIVE NOW!

The PSYCH Investor Summit: Research & Development is officially underway – but it isn’t too late to join in. Simply register for complimentary tickets and join us as we engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors.

Featured speakers include Rick Doblin, Founder of MAPS; Christian Angermayer, Founder of atai Life Sciences; Richard Carleton, CEO at the Canadian Securities Exchange; Greg McKee, CEO of Tryp Therapeutics; Roger McIntyre, CEO of Braxia Scientific; Yeji Jesse Lee, psychedelic-industry journalist at Business Insider; Dr Ben Sessa, Chief Medical Officer at Awakn Life Sciences; Dr Jennifer Mitchell, professor of neurology and psychiatry, UCSF; Daniel Sanders, Chief Scientific Officer of Gwella; and Floris Wolswijk, Founder at Blossom.

Check out the schedule for full details. Hope to see you there!

The Trajectory and Importance of Psychedelic Clinical Trials

Clinical trials are an essential building block in the development of psychedelic medicine, as the data informs the FDA, and other regulators, on the drug’s safety and suitability for medical application. As a result, drug developers rely on this scientific evidence to secure regulatory approval and pave the treatment’s route to market.

In anticipation of the third Psychedelics as Medicine Report, PSYCH has collaborated with psychedelics data and analytics experts Blossom to examine the current state of clinical trials and what their impacts on global healthcare will be.

TRYP THERAPEUTICS TO TREAT PSYCHIATRIC DISORDERS WITH SYNTHETIC PSILOCYBIN

This year’s PSYCH Investor Summit: Research & Development presents investors with the opportunity to examine Tryp Therapeutics.

BRAXIA SCIENTIFIC IDENTIFIES SHORT-TERM ROI IN PSYCHEDELIC MEDICINE

As the excitement builds around the FDA’s potential support of psilocybin, ketamine-derived medicines have largely flown under the radar.

BUSINESS AND INVESTMENT

Psilera raises US$2.5m for extended-release DMT patch .

Numinus Wellness to acquire Neurology Centre of Toronto.

COMPASS Pathways partners with King’s College London and NHS Foundation Trust.

Cybin partners with Greenbrook TMS to create mental health centres.

Delic completes acquisition of Ketamine Infusion Centers LLC.

NanoPsy Inc. closes seed round with CA$500,000 raised.

PurMinds completes investment in IMIO Life.

Psyched Wellness appoints Matthew Singh as CPG and branding consultant.

Delic announces partnership with Agilent Technologies.

Entheon Biomedical appoints Dr Dinesh Bhayana as a medical advisor.

RESEARCH AND SCIENCE

Author Michael Pollan explores the human relationship with psychoactive plants.

Psilocybin increases neuron connections in mice.

Psyched Wellness’ Amanita extract safe on animals.

Mynd Life Sciences studies potential for ‘vaccine’ for depression.

Psyence partners with Clerkenwell Health for palliative care clinical trial.

Psychedelic drugs moving from the fringe to mainstream of health.

A trip inside a peyote desert pilgrimage.

Seelos Therapeutics administers racemic ketamine in patient study.

Harvard launches research into psychedelics and law.

REGULATION AND LEGISLATION

Third California city seeks to decriminalise psychedelics.

Maine Senate defeats drug decriminalisation bill.

Cancer patient faces lengthy wait for approval for psilocybin treatment.